ClinVar Miner

Submissions for variant NM_000256.3(MYBPC3):c.3384G>C (p.Glu1128Asp)

gnomAD frequency: 0.00009  dbSNP: rs375116558
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine RCV000035585 SCV000059235 uncertain significance not specified 2018-05-18 criteria provided, single submitter clinical testing Variant classified as Uncertain Significance - Favor Benign. The p.Glu1128Asp va riant in MYBPC3 has been identified in 1 individual with DCM (Gable 2014) and 1 individual with HCM (LMM data), but has also been identified in 0.017% (21/12346 6) of European chromosomes by the Genome Aggregation Database (gnomAD, http://gn omad.broadinstitute.org; dbSNP rs375116558). It has been reported in ClinVar (Va riant ID:42710). Computational prediction tools and conservation analysis sugges t that the p.Glu1128Asp variant may not impact the protein, though this informat ion is not predictive enough to rule out pathogenicity. In summary, while the c linical significance of the p.Glu1128Asp variant is uncertain, these data sugges t that it is more likely to be benign. ACMG/AMP criteria applied: BP4.
GeneDx RCV000766372 SCV000208168 uncertain significance not provided 2018-05-23 criteria provided, single submitter clinical testing A variant of uncertain significance has been identified in the MYBPC3 gene. The E1128D variant has not been published as pathogenic or been reported as benign to our knowledge. This variant is observed in 21/123466 (0.02%) alleles from individuals of European (non-Finnish) ancestry in large population cohorts (Lek et al., 2016). The E1128D variant is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties. Finally, in-silico analyses, including protein predictors and evolutionary conservation, support that this variant does not alter protein structure/function. Therefore, based on the currently available information, it is unclear whether this variant is pathogenic or rare benign.
Invitae RCV000465772 SCV000546425 likely benign Hypertrophic cardiomyopathy 2024-01-24 criteria provided, single submitter clinical testing
Color Diagnostics, LLC DBA Color Health RCV001188108 SCV001355080 uncertain significance Cardiomyopathy 2023-02-02 criteria provided, single submitter clinical testing This missense variant replaces glutamic acid with aspartic acid at codon 1128 of the MYBPC3 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in an individual affected with hypertrophic cardiomyopathy (PMID: 25611685), an individual affected with dilated cardiomyopathy (doi:10.1136/heartjnl-2016-309890.210), and in a case of sudden unexplained death (PMID: 27930701). This variant has been identified in 23/273044 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.